Experimental cancer pill RP-1664 fails to launch: phase 1 trial halted
NCT ID NCT06232408
First seen Nov 21, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This early-stage study tested an experimental oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The study was terminated early, and results are not yet available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Participating Site 1004
New York, New York, 10065, United States
-
Participating Site 1008
New York, New York, 10032, United States
-
Participating Site 1012
New Haven, Connecticut, 06519, United States
-
Participating Site 1025
San Francisco, California, 94143, United States
-
Participating Site 4001
Copenhagen, Denmark
Conditions
Explore the condition pages connected to this study.